|
Hyaluronidase Deficiency
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes.
|
27604308 |
2016 |
|
Hyaluronidase Deficiency
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Biology of hyaluronan: Insights from genetic disorders of hyaluronan metabolism.
|
26322170 |
2015 |
|
Hyaluronidase Deficiency
|
0.900 |
Biomarker
|
disease |
MGD |
A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis.
|
18344557 |
2008 |
|
Hyaluronidase Deficiency
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX.
|
10339581 |
1999 |
|
Hyaluronidase Deficiency
|
0.900 |
GermlineCausalMutation
|
disease |
ORPHANET |
Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX.
|
10339581 |
1999 |
|
Hyaluronidase Deficiency
|
0.900 |
GeneticVariation
|
disease |
UNIPROT |
Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX.
|
10339581 |
1999 |
|
Hyaluronidase Deficiency
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Clinical and biochemical manifestations of hyaluronidase deficiency.
|
8793927 |
1996 |
|
Hyaluronidase Deficiency
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Hyaluronidase Deficiency
|
0.900 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Hyaluronidase Deficiency
|
0.900 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Pulmonary Hypertension
|
0.200 |
Biomarker
|
phenotype |
RGD |
The present data demonstrate that, in the MCT model, early-stage PH is associated with enhanced hyaluronidase-1 activity, while both degradation and synthesis are increased at later stages.
|
19915162 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hyaluronidase-1 expression was measured by RT-PCR in normal and tumour tissue samples; hyaluronic acid values of saliva and tumour tissues were measured by ELISA method.
|
31207115 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated the role of exosomally shed Hyal1 in modulating tumor cell autonomous functions and in modifying the behavior of prostate stromal cells.
|
29753676 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor cell-derived hyaluronidase HYAL-1 degrades hyaluronic acid (HA) into angiogenic fragments (AGF: 10-12 disaccharides).
|
27419371 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To minimize the premature release, hyaluronic acid (HA) was further coating on the outer surface of pSiO<sub>2</sub>, which would be degraded by over-expressed hyaluronidase (Hyal-1) in the tumor microenvironment.
|
28888002 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, brain metastatic tissue showed a significantly reduced HYAL1 expression compared with the corresponding primary tumor (p = 0.003).
|
28168629 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor stage (P = .019) and HYAL-1 (P = .046) transcript levels were also associated with disease-specific mortality.
|
20960509 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor cell-derived hyaluronidase (HAase) HYAL-1 degrades hyaluronic acid (HA) into proangiogenic fragments that support tumor progression.
|
21555367 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we examined pathways responsible for effects of HAS3 and Hyal1 on tumor cell phenotype.
|
21315068 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Upregulation of HYAL1 expression in breast cancer promoted tumor cell proliferation, migration, invasion and angiogenesis.
|
21829529 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results identify Hyaluronidase-1 as a potential target/biomarker for clear cell and mucinous EOCs and especially in tumors with low ERα levels.
|
21695196 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumours grew in eight mice inoculated with HYAL1.
|
18725949 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Structure of human hyaluronidase-1, a hyaluronan hydrolyzing enzyme involved in tumor growth and angiogenesis.
|
17503783 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HYAL1 expression in bladder cancer cells promotes tumor growth, invasion, and angiogenesis.
|
17145867 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of Hyal 3 and Hyal 2 mRNA were >1000-fold and >30-fold greater respectively than that of Hyal 1 mRNA, the major Hyal expressed in other cancers.No Hyal type varied with tumor grade.
|
15936804 |
2005 |